Kezar Life Sciences, Inc. (KZR) Financial Statements (2026 and earlier)

Company Profile

Business Address 4000 SHORELINE COURT, SUITE 300
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments71,878,00090,216,000100,849,000114,361,000132,245,000148,388,000
Cash and cash equivalent71,878,00038,935,00034,367,00037,002,00041,749,00034,858,000
Short-term investments  51,281,00066,482,00077,359,00090,496,000113,530,000
Receivables1,925,0002,002,0001,995,0002,199,000424,000 
Prepaid expense663,000975,000200,000634,000925,0001,037,000
Asset, held-for-sale, not part of disposal group 520,000     
Other undisclosed current assets746,0001,308,0001,658,0003,124,0003,894,0006,954,000
Total current assets:75,732,00094,501,000104,702,000120,318,000137,488,000156,379,000
Noncurrent Assets
Operating lease, right-of-use asset749,0001,050,0001,340,0001,618,0001,886,0002,143,000
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization 166,0002,175,0002,407,0002,650,0002,893,0003,149,000
Other noncurrent assets   674,000674,0002,415,0002,415,000
Total noncurrent assets:915,0003,225,0004,421,0004,942,0007,194,0007,707,000
TOTAL ASSETS:76,647,00097,726,000109,123,000125,260,000144,682,000164,086,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,248,0004,838,0005,264,0008,081,00011,586,00013,125,000
Accounts payable507,000911,0001,157,0001,966,0003,651,0003,461,000
Accrued liabilities3,741,0003,927,0004,107,0006,115,0007,935,0009,664,000
Debt  5,279,0005,293,0005,217,0005,217,0003,913,000
Other undisclosed current liabilities2,326,0003,259,0003,808,0003,665,0003,526,0003,391,000
Total current liabilities:6,574,00013,376,00014,365,00016,963,00020,329,00020,429,000
Noncurrent Liabilities
Long-term debt and lease obligation  1,374,0002,628,0003,874,0005,111,0006,349,000
Long-term debt, excluding current maturities  1,374,0002,628,0003,874,0005,111,0006,349,000
Liabilities, other than long-term debt   344,0001,354,0002,326,0003,259,000
Operating lease, liability   344,0001,354,0002,326,0003,259,000
Total noncurrent liabilities:  1,374,0002,972,0005,228,0007,437,0009,608,000
Total liabilities:6,574,00014,750,00017,337,00022,191,00027,766,00030,037,000
Equity
Equity, attributable to parent70,073,00082,976,00091,786,000103,069,000116,916,000134,049,000
Common stock7,0007,0007,0007,0007,0007,000
Additional paid in capital560,598,000558,941,000556,805,000554,349,000551,570,000548,216,000
Accumulated other comprehensive income (loss)  14,000(267,000)(232,000)(162,000)107,000
Accumulated deficit(490,532,000)(475,986,000)(464,759,000)(451,055,000)(434,499,000)(414,281,000)
Total equity:70,073,00082,976,00091,786,000103,069,000116,916,000134,049,000
TOTAL LIABILITIES AND EQUITY:76,647,00097,726,000109,123,000125,260,000144,682,000164,086,000

Income Statement (P&L) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Operating expenses(15,164,000)(11,715,000)(14,599,000)(17,629,000)(21,563,000)(21,948,000)
Operating loss:(15,164,000)(11,715,000)(14,599,000)(17,629,000)(21,563,000)(21,948,000)
Nonoperating income
(Investment Income, Nonoperating)
801,0001,026,0001,197,0001,420,000  
Interest and debt expense   (302,000)(347,000)  
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes (146,000)   6,869,000 
Loss from continuing operations before equity method investments, income taxes:(14,509,000)(10,689,000)(13,704,000)(16,556,000)(14,694,000)(21,948,000)
Other undisclosed loss from continuing operations before income taxes (1,224,000)     
Loss from continuing operations:(15,733,000)(10,689,000)(13,704,000)(16,556,000)(14,694,000)(21,948,000)
Other undisclosed net loss     (5,524,000) 
Net loss:(15,733,000)(10,689,000)(13,704,000)(16,556,000)(20,218,000)(21,948,000)
Other undisclosed net income (loss) attributable to parent1,187,000(538,000)   1,635,000
Net loss available to common stockholders, diluted:(14,546,000)(11,227,000)(13,704,000)(16,556,000)(20,218,000)(20,313,000)

Comprehensive Income (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(15,733,000)(10,689,000)(13,704,000)(16,556,000)(20,218,000)(21,948,000)
Comprehensive loss:(15,733,000)(10,689,000)(13,704,000)(16,556,000)(20,218,000)(21,948,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,173,000(257,000)(35,000)(70,000)(269,000)2,127,000
Comprehensive loss, net of tax, attributable to parent:(14,560,000)(10,946,000)(13,739,000)(16,626,000)(20,487,000)(19,821,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: